Printer Friendly

IMUTEC CORPORATION PHASE II STUDY OF VIRULIZIN IN PATIENTS WITH PANCREATIC CANCER RELEASED

 IMUTEC CORPORATION PHASE II STUDY OF VIRULIZIN
 IN PATIENTS WITH PANCREATIC CANCER RELEASED
 TORONTO, Sept. 16 /PRNewswire/ -- IMUTEC Corporation (formerly RML Medical Laboratories Inc.) today commented on the results of a Phase II study of VIRULIZIN(TM) in patients with pancreatic cancer conducted at St. Michael's Hospital and the Toronto Hospital.
 The results were presented on Sept. 13 by the principal investigator, Dr. Ellen Warner of St. Michael's Hospital, at the 61st annual meeting of the Royal College of Physicians and Surgeons of Canada in Ottawa, Ontario.
 The study was established to determine the safety and efficacy of VIRULIZIN in the treatment of pancreatic cancer. All 22 patients enrolled in the study were evaluable for safety -- 17 were evaluable for efficacy.
 To date, a total of 570 injections of VIRULIZIN have been administered to the 22 patients. No toxic side effects have been observed and the investigators reported no concerns regarding the safety of VIRULIZIN.
 "These results strengthen our belief that VIRULIZIN is a relatively non-toxic agent that does not produce the side effects and safety concerns common to cytotoxic immuno-suppressant therapeutics such as chemotherapy and therapeutic radiation," said Dr. Judith A. Burgess, medical director of IMUTEC Corporation.
 Of the 17 patients evaluable for efficacy, the median and mean survival from diagnosis was eight and 10 months and the median and mean survival from the commencement of treatment was four and six months. Six patients (36 percent) had "stable disease" for three months or longer. Included in this group was a patient in whom the disease remained stable for nine months and who survived 27 months from the date of diagnosis and two other patients where the disease continues to remain stable eight and 10 months after the commencement of treatment. In addition, Warner reported that another patient diagnosed with pancreatic cancer is currently being treated with VIRULIZIN outside of the clinical protocol and has remained stable for almost 12 months.
 "We are particularly encouraged by these early results given that the median survival from diagnosis for pancreatic patients is normally three to six months and that this trial was not based upon the new increased schedule of treatment which was approved by our Medical Advisory Board in March of this year," said Dr. Phil Gold, chairman of IMUTEC's Medical Advisory Board. "The latest clinical trials in Mexico are based upon a protocol with an increased dosing schedule and all future trials in Canada, the United States and Europe will be based upon the new schedule," added Gold.
 "When this trial began in August 1990 our major objectives were to determine the safety of VIRULIZIN as well as its effect on patient survival and quality of life for a cancer indication that is currently unresponsive to conventional therapy," said Gold. "While Dr. Warner's early clinical results did not indicate a reduction in the tumor size for the evaluable patients, the safety and stability results are obviously promising and warrant further clinical trials with the new increased dosing schedule," he added.
 IMUTEC is a biotechnology company using a proprietary technology to develop and commercialize naturally derived immunologic pharmaceuticals for use in the treatment of diseases. To date, IMUTEC has applied its technology to produce VIRULIZIN, a potential new drug for the treatment of cancer.
 VIRULIZIN is currently undergoing Phase II clinical trials on the following types of cancer: pancreatic, malignant melanoma, kidney, stomach, and recurrent rectum and colon.
 -0- 9/16/92
 /CONTACT: David W. Cooke, 416-724-1100 or 800-561-9400, ext. 227, or fax, 416-724-1167, for IMUTEC/ CO: IMUTEC Corporation ST: Ontario IN: MTC SU:


CK -- NY027 -- 0042 09/16/92 10:56 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1992
Words:602
Previous Article:PAINEWEBBER INDEPENDENT LIVING MORTGAGE INC. II DECLARES DIVIDEND
Next Article:APPARELVISION PREMIERS SATELLITE NETWORK DEDICATED TO APPAREL INDUSTRY; DESIGNED TO REVOLUTIONIZE BUYING IN THE RETAIL INDUSTRY
Topics:


Related Articles
SCIENTIFIC DEVELOPMENTS ADD TO VIRULIZIN KNOWLEDGE BASE
IMUTEC REPORTS FIRST QUARTER RESULTS
PHASE II CLINICAL TRIAL RESULTS RELEASED - VIRULIZIN PROVIDES BENEFITS TO ADVANCED MALIGNANT MELANOMA PATIENTS
IMUTEC PURSUES PROGRAM OF PHASE III CLINICAL TRIALS
VIRULIZIN INCREASES SURVIVAL RATE IN ADVANCED MALIGNANT MELANOMA PATIENTS
Therion Biologics Corporation Receives FDA Agreement to Initiate Phase III Clinical Trial With PANVAC(TM)-VF In Advanced Pancreatic Cancer; --...
Researchers Present Results from Studies of Therion's Therapeutic Cancer Vaccines in Patients with Pancreatic Cancer; - Data presented today at ASCO...
Therion Biologics Corporation Initiates Phase III Clinical Trial With PANVAC(TM)-VF In Advanced Pancreatic Cancer.
Therion Announces Upcoming Oral and Poster Presentations at ASCO on Lead Programs in Prostate and Pancreatic Cancer.
Therion Announces Presentation of Follow-up Clinical Data Regarding Its Novel Targeted Cancer Therapy PANVAC-VF at ASCO.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters